Search academic texts

Information × Registration Number 0223U005801, 0121U112051 , R & D reports Title To determine the effectiveness of hormonotherapy in the complex treatment of patients with ovarian cancer or its recurrences. popup.stage_title Head Mikhanovskyi Oleksandr A., Доктор медичних наукSukhina Olena M., Доктор медичних наук Registration Date 31-12-2023 Organization State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine" popup.description2 Object of research: treatment of patients with ovarian cancer. The purpose of the study: to increase the effectiveness of complex treatment of ovarian cancer and recurrences of the disease by using hormone therapy based on the study of the level of expression of estrogen and progesterone receptors in the tumor and the content of sex hormones in the blood of patients. Research methods: clinical-instrumental, clinical, radiological, immunological, morphological, statistical. Theoretical and practical results: the theoretical result is the establishment of a relationship between the expression of MBM and the receptor status of the tumor in patients with OC. Moderate expression of Ki67 was determined in the majority of patients with OC (53.0%), regardless of the receptor status of the tumor. In patients with ER+ PR+ and ER− PR+ progesterone levels, the frequency of expression of positive Bcl2 was 2–2.5 times more frequent than that of negative Bcl2. In patients with estrogen-positive (ER+ PR−) and estrogen-negative (ER− PR+) tumor receptor status, positive expression of VEGF was determined 1.9–6 times more often. In patients with estrogen-positive (ER+ PR−) and estrogen-negative (ER− PR−, ER− PR+ ) tumor receptor status, negative expression of p53 was more often determined. The practical result - the method of treatment of ovarian cancer patients with estrogen-positive receptor status of the tumor, who were prescribed continuous anti-estrogen therapy with drugs - letrazol, tamoxifen or examimtan, was improved. Novelty: For the first time, ovarian cancer patients with estrogen-positive tumor receptor status (ER+ PR-, ER+ PR+) were prescribed continuous anti-estrogen therapy to prolong the relapse-free period and treat relapses. Effectiveness of implementation: none. Field of application: oncology. Product Description popup.authors Artamonova Neonila Olehivna Dolhaia Oksana Volodymyrivna Kantsedal Olena Mykolaivnа Krugova Iryna Mykolaivna Lanko Liliia Hryhorivna Lukashkova Olha Petrivna Moiseienko Yuliia Anatoliivna Muzhychuk Oleksij Volodymyrovych Starikov Volodymyr Ivanovich Teplova Maryna Anatoliivna Teslenko Iryna Mykolaivna Kharchenko Yuliia Volodymyrivna Shchyt Nataliia Mykolaivna popup.nrat_date 2023-12-31 Close